Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2051-1426

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors ; volume:7 ; number:1 ; day:24 ; month:1 ; year:2019 ; pages:1-11 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (24.1.2019), 1-11, 12.2019

Creator: Conroy, Jeffrey M.
Pabla, Sarabjot
Nesline, Mary K.
Glenn, Sean T.
Papanicolau-Sengos, Antonios
Burgher, Blake
Andreas, Jonathan
Giamo, Vincent
Wang, Yirong
Lenzo, Felicia L.
Bshara, Wiam
Khalil, Maya
Dy, Grace K.
Madden, Katherine G.
Shirai, Keisuke
Dragnev, Konstantin
Tafe, Laura J.
Zhu, Jason
Labriola, Matthew
Marin, Daniele
McCall, Shannon J.
Clarke, Jeffrey
George, Daniel J.
Zhang, Tian
Zibelman, Matthew
Ghatalia, Pooja
Araujo-Fernandez, Isabel
Cruz-Merino, Luis de la
Singavi, Arun
George, Ben
MacKinnon, Alexander C.
Thompson, Jonathan
Singh, Rajbir
Jacob, Robin
Kasuganti, Deepa
Shah, Neel
Day, Roger
Galluzzi, Lorenzo
Gardner, Mark
Morrison, Carl

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40425-018-0489-5

URN: urn:nbn:de:101:1-2019030121485504192986

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:57 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Conroy, Jeffrey M.
Pabla, Sarabjot
Nesline, Mary K.
Glenn, Sean T.
Papanicolau-Sengos, Antonios
Burgher, Blake
Andreas, Jonathan
Giamo, Vincent
Wang, Yirong
Lenzo, Felicia L.
Bshara, Wiam
Khalil, Maya
Dy, Grace K.
Madden, Katherine G.
Shirai, Keisuke
Dragnev, Konstantin
Tafe, Laura J.
Zhu, Jason
Labriola, Matthew
Marin, Daniele
McCall, Shannon J.
Clarke, Jeffrey
George, Daniel J.
Zhang, Tian
Zibelman, Matthew
Ghatalia, Pooja
Araujo-Fernandez, Isabel
Cruz-Merino, Luis de la
Singavi, Arun
George, Ben
MacKinnon, Alexander C.
Thompson, Jonathan
Singh, Rajbir
Jacob, Robin
Kasuganti, Deepa
Shah, Neel
Day, Roger
Galluzzi, Lorenzo
Gardner, Mark
Morrison, Carl
SpringerLink (Online service)

Other Objects (12)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Related objects

Reset password